<Internation Circulation>:And between those two drugs， which one are you thinking most about?

Suzanne Hughes:We’re hearing quite a bit about Dabigatran.  We’ve seen some good results from the RE_LY trial that indicate there may be few hemorrhagic complications.  However we know， right now， that Dabigatran is a twice-a-day drug which can be a challenge for patient adherence.  It looks promising and many people are talking about it.